Question 1

What is the Ras gene and why is it important in cancer research?

Accepted Answer

The Ras gene is a proto-oncogene that encodes a protein involved in cell signaling and growth regulation. When mutated, Ras becomes hyperactive, driving uncontrolled cell division and contributing to cancer development. Understanding Ras mutations is central to cancer research because they occur frequently in human tumors and represent a key target for therapeutic intervention.

Question 2

How do Ras mutations lead to cancer development?

Accepted Answer

Ras mutations alter the protein's structure, causing it to remain in an active state and continuously signal for cell growth. This persistent activation bypasses normal cellular checkpoints that prevent uncontrolled division. The mutated Ras protein drives excessive proliferation, allowing cells to accumulate additional mutations and progress toward malignancy.

Question 3

What are the different types of Ras gene mutations found in cancer?

Accepted Answer

Ras mutations typically occur at specific codons, most commonly at positions 12, 13, and 61. These point mutations result in amino acid substitutions that impair the protein's ability to hydrolyze GTP, locking Ras in its active form. Different mutation types are associated with distinct cancer types, reflecting tissue-specific vulnerabilities.

Question 4

How does normal Ras protein function in healthy cells?

Accepted Answer

Normal Ras protein acts as a molecular switch in cell signaling pathways, cycling between inactive GDP-bound and active GTP-bound states. When growth signals activate Ras, it recruits downstream effectors to promote controlled cell growth and division. GTPase activity then hydrolyzes GTP to GDP, returning Ras to its inactive state and terminating the signal.

Question 5

What percentage of human cancers involve Ras gene mutations?

Accepted Answer

Ras mutations are among the most common oncogenic alterations in human cancer, occurring in approximately 30% of all tumors. Specific cancer types show higher frequencies, with pancreatic cancer exceeding 90% and colorectal cancer around 50%. This prevalence makes Ras a critical focus for understanding cancer biology and developing targeted therapies.

Question 6

Why is targeting Ras mutations challenging for cancer treatment?

Accepted Answer

Ras proteins lack obvious binding pockets for small-molecule inhibitors, making direct drug targeting difficult. The protein's high affinity for GTP and rapid nucleotide exchange complicate therapeutic approaches. Recent advances in allele-specific inhibitors and combination strategies are beginning to overcome these challenges, offering new hope for Ras-driven cancers.

גן ראס

Browse More Videos